ライフサイエンスコーパス: endothelin receptor

1 models of CHF by nonselectively antagonizing endothelin receptors.

2 bofibrosis, which were prevented by blocking endothelin receptors.

3 y infusion of BQ123 (an antagonist of type A endothelin receptors, 1 micromol/min).

4 O sythetase, endothelin-1 (EDN1 rs5370), and endothelin receptor A (EDNRA rs5335) may influence ROP d

5 these sites in branchial arch extracts from endothelin receptor A (EdnrA) mutant and wild-type mouse

6 y by Jagged-Notch signaling and ventrally by endothelin receptor A (EDNRA) signaling.

7 s [endothelin-1 (ET-1), endothelin-3 (ET-3), endothelin receptor A (EdnrA), EdnrB] were determined ov

8 The mRNA levels of prepro-ET-1, endothelin receptor A (ET(A)), and endothelin receptor B

9 Endothelin receptor A (ETA), a G protein-coupled recepto

10 reast cancer cells through interference with endothelin receptor A (ETA).

11 In contrast, the endothelin receptor A (ETRA) antagonist BQ123 does not h

12 actility-related genes such as endothelin-1, endothelin receptor A and B, adrenomedullin, adrenomedul

13 Endothelin receptor A and p66Shc regulate spontaneous Ca

14 ontaining structural analogs of the marketed endothelin receptor A antagonist Ambrisentan, were ident

15 s controlled by treatment with the selective endothelin receptor A antagonist BQ-123 in a dose-depend

16 Endothelin receptor A antagonist BQ123 dramatically redu

17 Endothelin receptor A blockade in vitro did not improve

18 angiogenesis by Edn2 requires expression of Endothelin receptor A but not Endothelin receptor B in t

19 Conditional loss of endothelin receptor A in granulosa cells also decreased

20 heir spontaneous motion via the endothelin-1/endothelin receptor A pathway.

21 inic acetylcholine receptor, heme oxygenase, endothelin receptor A, haptoglobin, tyrosine aminotransf

22 iomas (eg, growth hormone receptor, IGFBP-7, endothelin receptor A, IGF2).

23 receptor 1), roundabout homologue 2 (ROBO2), endothelin receptor A, soluble urokinase plasminogen act

24 ncreased cell surface expression of CCR7 via endothelin receptor A.

25 The finding of associations between endothelin receptors A and B and distinct clinical and i

26 stituted pyrrolidine-3-carboxylic acid based endothelin receptor-A antagonist.

27 The selective endothelin receptor-A antagonists sitaxsentan and ambris

28 e discovery of amidothiophenesulfonamides as endothelin receptor-A antagonists with high potency and

29 show that zebrafish harbouring a mutation in endothelin receptor aa (ednraa) form less cohesive shoal

30 The consequences of endothelin receptor activation were examined in atrial t

31 c receptors, alpha-adrenergic receptors, and endothelin receptors (among others) have been associated

32 Pretreatment with endothelin receptor and selectin inhibitors blocked the

33 q/11) formed immunocomplexes with the type-A endothelin receptor and the 110alpha subunit of PI 3-kin

34 d podocyte loss through direct activation of endothelin receptors and NF-kappaB and beta-catenin path

35 ps Y-27632-treatment increased expression of endothelin receptors and of parathyroid hormone-like hor

36 ins, suggesting a functional linkage between endothelin receptors and the Gardos channel.

37 on of IL-6, transforming growth factor beta, endothelin receptor, and alpha-smooth muscle actin by no

38 henesulfonamides with potent ET(A)-selective endothelin receptor antagonism and the subsequent identi

39 Endothelin receptor antagonism has emerged as an importa

40 fibroblasts, consistent with the notion that endothelin receptor antagonism may be beneficial in cont

41 designed to test the hypothesis that chronic endothelin receptor antagonism preserves coronary endoth

42 Chronic endothelin receptor antagonism preserves coronary endoth

43 The current study demonstrates that chronic endothelin receptor antagonism prevents the increase in

44 Chronic endothelin receptor antagonism significantly increased c

45 Endothelin-receptor antagonism with oral bosentan is an

46 Endothelin receptor antagonist (ERA) and phosphodiestera

47 i) may offset fluid retaining effects of the endothelin receptor antagonist (ERA) atrasentan while ef

48 Administration of an endothelin receptor antagonist (ETRA, SB 209670) to dogs

49 Three patients required PH treatment with endothelin receptor antagonist (n=2) or calcium channel

50 144-363 d) after the initial combination of endothelin receptor antagonist + phosphodiesterase-5 inh

51 ciated PH and 27 of 39 with PAH) received an endothelin receptor antagonist as initial therapy.

52 R trial assessed the association between the endothelin receptor antagonist atrasentan and pain and p

53 Treatment with the endothelin receptor antagonist bosentan may be effective

54 The endothelin receptor antagonist BQ-485 (ET(A) selective)

55 In many studies, such as the Study with an Endothelin Receptor Antagonist in Pulmonary Arterial Hyp

56 The endothelin receptor antagonist is among the most effecti

57 The endothelin receptor antagonist macitentan has demonstrat

58 us epoprostenol were weaned off post-LT, and endothelin receptor antagonist or phosphodiesterase type

59 These effects were prevented by the endothelin receptor antagonist PD145065 (10 microM) and

60 Administration of a nonselective endothelin receptor antagonist provided essentially equi

61 udy examined the effects of the nonselective endothelin receptor antagonist SB-209,670, and the less

62 The endothelin receptor antagonist tezosentan did not improv

63 Tezosentan is a dual endothelin receptor antagonist that has been shown to im

64 Tezosentan is an intravenous short-acting endothelin receptor antagonist that has favorable hemody

65 Ambrisentan is an oral, once-daily endothelin receptor antagonist that is selective for the

66 mendation for either prostacyclin agonist or endothelin receptor antagonist therapy and a strong reco

67 We used a specific endothelin receptor antagonist to determine whether ET-1

68 Increasing doses of the endothelin receptor antagonist zibotentan and lower eGFR

69 a 12-month trial of bosentan, a nonselective endothelin receptor antagonist, as a therapy for SSc-rel

70 BMS182874, an endothelin receptor antagonist, blocks the effects of ex

71 We investigated whether treatment with the endothelin receptor antagonist, bosentan, decreased the

72 Atrasentan, an endothelin receptor antagonist, has shown activity in pr

73 mineralocorticoid antagonist and a selective endothelin receptor antagonist, have now been demonstrat

74 he efficacy and safety of tezosentan, a dual endothelin receptor antagonist, in patients hospitalized

75 nd safety of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with moderat

76 sess the hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with PHT, in

77 Aprocitentan, a dual endothelin receptor antagonist, is the first agent from

78 ar Disease]), we evaluated the effects of an endothelin receptor antagonist, macitentan, in patients

79 n of the endothelin system with bosentan, an endothelin receptor antagonist, was strongly protective

80 tment naive or on background therapy with an endothelin receptor antagonist, were eligible.

81 the current practice of adding bosentan, an endothelin receptor antagonist.

82 liminary study, the orally administered dual endothelin-receptor antagonist bosentan improved exercis

83 The endothelin-receptor antagonist bosentan is beneficial in

84 the efficacy and safety of bosentan, a dual endothelin-receptor antagonist that can be taken orally,

85 essed the efficacy of macitentan, a new dual endothelin-receptor antagonist, using a primary end poin

86 ral phosphodiesterase-5 inhibitor or an oral endothelin-receptor antagonist.

87 Endothelin receptor antagonists (ERA) and phosphodiester

88 Preclinical studies have demonstrated that endothelin receptor antagonists (ERAs) can reduce or pre

89 Oral endothelin receptor antagonists (ERAs) have been shown t

90 Endothelin receptor antagonists (ERAs) reduce albuminuri

91 Selective endothelin receptor antagonists (ERAs) that target the e

92 s of disease-targeted therapy (predominantly endothelin receptor antagonists [47.3%] or phosphodieste

93 gated for the treatment of nmCRPC, including endothelin receptor antagonists and bone-targeted therap

94 -3-methyl-glutaryl-CoA reductase inhibitors, endothelin receptor antagonists and phosphodiesterase ty

95 Conversely, endothelin receptor antagonists and/or KIT blocking anti

96 Endothelin receptor antagonists are first-line therapy f

97 hese findings raise the possibility of using endothelin receptor antagonists as neuroprotective agent

98 These data do not support the use of endothelin receptor antagonists as therapy for ILD secon

99 Endothelin receptor antagonists have emerged as a novel

100 rable hemodynamic and neurohormonal effects, endothelin receptor antagonists have not improved outcom

101 Endothelin receptor antagonists have revolutionized the

102 data support a potential role for selective endothelin receptor antagonists in protecting renal func

103 roenvironment and further support the use of endothelin receptor antagonists in the treatment of inva

104 changes of HPS and the effects of selective endothelin receptor antagonists in vivo were assessed af

105 Additionally, infusion of endothelin receptor antagonists into the bursa of wild-t

106 Moreover, endothelin receptor antagonists may have a therapeutic r

107 The vasodilator properties of endothelin receptor antagonists may prove valuable thera

108 y hypoxia but attenuated by either selective endothelin receptor antagonists or oligonucleotides targ

109 were receiving riociguat in combination with endothelin receptor antagonists or prostanoids, or both.

110 For instance, macitentan and bosentan from endothelin receptor antagonists show major concern while

111 g at the identification of novel potent dual endothelin receptor antagonists with high oral efficacy.

112 ple, with phosphodiesterase 5 inhibitors and endothelin receptor antagonists) and, if necessary, the

113 he treatment of PAH: prostacyclin analogues, endothelin receptor antagonists, and phosphodiesterase t

114 s sodium-glucose cotransporter 2 inhibitors, endothelin receptor antagonists, glucagon-like peptide 1

115 In cells treated with endothelin receptor antagonists, hydrogen peroxide scave

116 ials continue to explore new applications of endothelin receptor antagonists, particularly in treatme

117 erent classes of drugs are now available-ie, endothelin receptor antagonists, phosphodiesterase-5 inh

118 Novel agents, including endothelin receptor antagonists, pyruvate kinase activat

119 ts, which have been previously attributed to endothelin receptor antagonists, were more frequent in t

120 as aldosterone synthase inhibitors and dual endothelin receptor antagonists, whereas others may prov

121 mineralocorticoid receptor antagonists, and endothelin receptor antagonists.

122 se biological effects that are unaffected by endothelin receptor antagonists.

123 terase type 5 inhibitors, sodium nitrite and endothelin receptor antagonists.

124 bitors, niacin, inhaled carbon monoxide, and endothelin receptor antagonists.

125 Endothelin-receptor antagonists are in clinical use to t

126 hypertension and patients who were receiving endothelin-receptor antagonists or (nonintravenous) pros

127 the disease and in those who were receiving endothelin-receptor antagonists or prostanoids.

128 Although endothelin-receptor antagonists reduce albuminuria in di

129 pulmonary arterial hypertension, other than endothelin-receptor antagonists, was allowed at study en

130 ALK5 inhibition and endothelin receptor antagonization inhibited mesenchymal

131 Endothelin receptors are also expressed on the human ecc

132 sults indicate that at least two subtypes of endothelin receptors are present on canine bronchial smo

133 Endothelin receptors are widely distributed throughout a

134 The number of endothelin receptors associated with bronchial contracti

135 Pharmacological antagonists of endothelin receptors attenuate cardiac hypertrophy, have

136 have identified alterations in expression of endothelin receptor B (EDNRB) as a potential factor that

137 The 5' region for the endothelin receptor B (EDNRB) gene is a complex CpG isla

138 damage also leads to a >10-fold increase in endothelin receptor B (Ednrb) in Muller cells 24 h after

139 Endothelin receptor B (EDNRB) is a G-protein-coupled rec

140 Animal models of endothelin receptor B (EdnrB) mutation reliably model hu

141 Loss of Endothelin-3/Endothelin receptor B (EDNRB) signaling leads to agangli

142 ts in Hirschsprung disease, we observed that Endothelin receptor B (Ednrb)-deficient gut NCSCs engraf

143 on its visual environment by downregulating endothelin receptor B (EdnRBa) mRNA via DNA hypermethyla

144 known genes, 67-kDa laminin receptor (67LR), endothelin receptor B (ENDRB), Na+/K+-ATPase, Ku antigen

145 pro-ET-1, endothelin receptor A (ET(A)), and endothelin receptor B (ET(B)) were measured by quantitat

146 Here we demonstrate that the endothelin-endothelin receptor B (ETBR) signaling pathway confers r

147 Activation of the endothelin receptor B (ETRB) in cultured melanocyte prec

148 We observed that endothelin receptor B [ET-B (gene name EDNRB)], the rece

149 lling through the G protein-coupled receptor endothelin receptor B and PKC epsilon, regulates the num

150 The endothelin receptor B gene (Ednrb) encodes a G-protein-c

151 The endothelin receptor B gene, a possible tumor suppressor

152 The endothelin receptor B in iTAMs signals tumor-supportive

153 expression of Endothelin receptor A but not Endothelin receptor B in the neural retina.

154 nts with HSCR alongside the well-established endothelin receptor B knockout mouse model, we investiga

155 ing chromosomal deficiencies surrounding the endothelin receptor B locus collected during the Oak Rid

156 in the neural crest-conditional deletion of endothelin receptor B model of Hirschsprung-associated e

157 eported modifier of hypopigmentation for the endothelin receptor B mouse model of WS4.

158 Mutations in the genes encoding endothelin receptor-B (Ednrb) and its ligand endothelin-

159 in ganglion cell number, while inhibition of endothelin receptor-B (EDNRB) leads to severe hypogangli

160 fected in HSCR encodes the G protein-coupled endothelin receptor-B (EDNRB).

161 The G-protein coupled receptor, endothelin receptor-B, and its ligand, endothelin-3, are

162 es that depend on both the G-protein-coupled endothelin receptor b1 (ednrb1) and the kit-related fms

163 We show that rose corresponds to endothelin receptor b1 (ednrb1), an orthologue of amniot

164 We show that Endothelin receptor B2 (EDNRB2) and EphB2 are both deter

165 were undertaken to test the hypothesis that endothelin receptor blockade can reduce neointimal thick

166 earm vasodilatation, the systemic effects of endothelin receptor blockade in healthy humans are unkno

167 nels via a mechanism possibly independent of endothelin receptor blockade.

168 Endothelin-receptor blockade provides haemodynamic benef

169 This effect was inhibited by a nonselective endothelin receptor blocker and by a selective ET(B) rec

170 However, the endothelin receptor blocker bosentan prevented the reduc

171 Bosentan, a dual endothelin receptor blocker, has been used clinically to

172 Pretreatment with PD 145065 (a nonselective endothelin receptor blocker; 50 micrograms.kg-1.min-1) c

173 ts may constitute the mechanism of action of endothelin receptor blockers in DN.

174 safety profiles, including SGLT2 inhibitors, endothelin receptor blockers, targeted-release budesonid

175 cted patients with essential hypertension to endothelin receptor blockers.

176 uid and that inhibition of B- but not A-type endothelin receptors blunts the decreased HCO3 secretion

177 animals given a specific inhibitor of A-type endothelin receptors (BQ-123) did not (-2.0+/-0.2 pmol m

178 Availability of cDNA clones for endothelin receptors can facilitate our understanding of

179 nearly abolished by PKC-IP, indicating that endothelin receptors could still activate PKC in 10 mm d

180 ctional role for PKCepsilon as a mediator of endothelin receptor-dependent increases in cytosolic cal

181 ing that PKCepsilon plays a critical role in endothelin receptor-dependent increases in intracellular

182 T assay used here provides new insights into endothelin-receptor dimer function, and represents a uni

183 iogenic mediators, including endothelins and endothelin receptor (EDNR) A.

184 helin family member Edn3, acting through the endothelin receptor EdnrA, directs extension of axons of

185 Endothelin ligands (Edns) and endothelin receptors (Ednrs) are unique to vertebrates(3

186 of diabetes, include use of drugs that block endothelin receptors (eg, atrasentan) and non-steroidal

187 he purpose of this study was to determine if endothelin receptor (ET-R) blockade during HPP would imp

188 logical blocking or genetic ablation of both endothelin receptors, ET(A) and ET(B), impedes dermal sh

189 onstrate that mice deficient for one type of endothelin receptor, ETA, mimic the human conditions col

190 he endothelin axis and in particular the two endothelin receptors, ETA and ETB, are targets for thera

191 The endothelin receptors, ETA and ETB, have differential tis

192 The predominant endothelin receptor expressed by normal prostate epithel

193 our knowledge of endothelin-1 synthesis and endothelin receptor expression and function in normal an

194 scular endothelial nitric oxide synthase and endothelin receptor expression and impaired exercise tol

195 evated ET-1 and the cell-specific pattern of endothelin receptor expression suggest that the endothel

196 tions, infarct volume, oxidative stress, and endothelin receptors following permanent middle cerebral

197 Blockade of endothelin receptors for 28 days with only a mixed ET(A)

198 et-monocyte aggregates, and altered monocyte endothelin receptor function, reflecting reduced endothe

199 bosentan (10 mg/kg) to inhibit A- and B-type endothelin receptors had higher HCO3 secretion than base

200 Most recently the Endothelin receptor has been implicated in multiple tumo

201 Experiments were designed to characterize endothelin receptors in bronchi and parenchyma of transp

202 ednra and ednrb, the genes encoding the two Endothelin receptors in mice, were born at predicted Men

203 ortant vasoregulatory molecule, the roles of endothelin receptors in specific cell types are not yet

204 The Value of Endothelin Receptor Inhibition With Tezosentan in Acute

205 Furthermore, depletion of EDN1 or the use of endothelin receptor inhibitors bosentan and ambrisentan

206 development and suggest that modification of endothelin receptor-ligand specificity was a key step in

207 fore, the thrombin, LPA, thromboxane A2, and endothelin receptors may be able to couple to Galpha12/1

208 bination with BQ123 (an antagonist of type A endothelin receptors) or phentolamine (used as a control

209 Endothelin receptors, particularly the ET(A) receptor, h

210 These data further implicate dysregulated endothelin-receptor pathways in fibroblasts in the patho

211 In mice, podocyte-specific knockout of the endothelin receptor prevented the diabetes-induced incre

212 ated by activation of the melanocortin 1 and endothelin receptors, respectively.

213 cells were injected in mice treated with the endothelin receptor-specific antagonist, atrasentan, the

214 These findings indicate that the pathway for endothelin receptor stimulation of MAPK involves PKCepsi

215 s study, we have examined the effects of the endothelin receptor subtype A antagonist, Ro 61-1790, on

216 that retained full receptor affinity at both endothelin receptor subtypes along with enhanced proteol

217 ve for the ET(A) (BQ-485) and ET(B) (BQ-788) endothelin receptor subtypes.

218 , the coupling of seven-transmembrane domain endothelin receptors to Gz proteins provided a pathway t

219 The endothelin receptor type A (EDNRA) signaling pathway is

220 s the peptide ligand Endothelin 1 (Edn1) and Endothelin receptor type A (Ednra), which are required f

221 2 activate two G protein-coupled receptors - endothelin receptor type A (ET(A)) and endothelin recept

222 and growth of the mammalian heart by binding endothelin receptor type A (ET(A)) and endothelin recept

223 dothelin (ET) 1 and angiotensin (Ang) II via endothelin receptor type A (ETAR) and Ang receptor type-

224 ogenesis of BMSCs was attenuated by blocking endothelin receptor type A (ETAR) and/or endothelin rece

225 dium-glucose cotransporter 2 inhibition plus endothelin receptor type A blockade in ZENITH-CKD), aldo

226 on chromosome 4q31.23, immediately 5' of the endothelin receptor type A with P = 2.2 x 10(-8) [odds r

227 ing the RET receptor tyrosine kinase and the endothelin receptor type B (EDNRB) are central to the ge

228 ncoding the RET receptor tyrosine kinase and endothelin receptor type B (EDNRB) are involved in HSCR

229 We identified the endothelin receptor type B (Ednrb) as a specific marker

230 we show the role of endothelin 3 (EDN3) and endothelin receptor type B (EDNRB) in promoting the brow

231 Mutations in the gene encoding the endothelin receptor type B (EDNRB) produce congenital ag

232 primarily determined by genetic variation at endothelin receptor type B (EDNRB), corin serine peptida

233 One of the genes associated with HSCR is endothelin receptor type B (Ednrb).

234 ors - endothelin receptor type A (ET(A)) and endothelin receptor type B (ET(B)) - with equal affinity

235 nding endothelin receptor type A (ET(A)) and endothelin receptor type B (ET(B)) G-protein-coupled rec

236 These cells highly expressed endothelin receptor type B (ETB(R)) and Jagged1, a Notch

237 The endothelin receptor type B (ETBR) regulates water and el

238 ing endothelin receptor type A (ETAR) and/or endothelin receptor type B (ETBR).

239 otein endothelin 3 (EDN3), its receptor (the endothelin receptor type B [EDNRB]), and the transcripti

240 , small molecule agonists and antagonists of endothelin receptor type B administered in slice culture

241 as a regenerative pathway and suggests that endothelin receptor type B agonists represent a promisin

242 Antagonists of endothelin receptor type B also inhibited remyelination

243 phatase 2 was validated, and upregulation of endothelin receptor type B and interleukin-18 was valida

244 rk therefore identifies endothelin 2 and the endothelin receptor type B as a regenerative pathway and

245 n post-mortem tissue revealed high levels of endothelin receptor type B in oligodendrocyte lineage ce

246 genome sequencing, we discovered that EDNRB (Endothelin receptor type B) is a candidate gene involved

247 rs, eNOS (endothelial NO synthase) and ETBR (endothelin receptor type B) receptors for assessments of

248 and significantly increase the expression of endothelin receptors upon maturation.

249 Endothelin receptors were still functional in 10 mm d-gl

250 Indeed, blockade of ETA endothelin receptors with BQ-610 (1 microM), similar to

251 protein ligands (in rodents), c-Kit, and the endothelin receptors with their ligands.